Literature DB >> 1317149

In vitro activities of three of the newer quinolones against anaerobic bacteria.

H M Wexler1, E Molitoris, S M Finegold.   

Abstract

The antimicrobial activities of three new quinolone compounds, sparfloxacin, temafloxacin, and WIN 57273, against anaerobic bacteria were determined in three separate studies. The Wadsworth agar dilution technique using brucella-laked blood agar was used throughout. The activities of other antimicrobial agents, including ciprofloxacin, imipenem, chloramphenicol, metronidazole, cefotetan, cefoxitin, and amoxicillin-clavulanic acid, were also determined. The breakpoints of the new quinolones were 2 micrograms/ml for sparfloxacin and WIN 57273 and 4 micrograms/ml for temafloxacin. WIN 57273 displayed very good activity against anaerobes, inhibiting all strains of Bacteroides fragilis group species at 2 micrograms/ml. Only two strains of Fusobacterium species were resistant (MIC, 4 micrograms/ml). Sparfloxacin inhibited 78% of B. fragilis strains and 44% of other B. fragilis group isolates at 2 micrograms/ml. At 2 micrograms/ml, the percentages of other anaerobic species susceptible were as follows: B. gracilis, 70%; other Bacteroides species, 61%; Clostridium species, 50%; Fusobacterium species, 70%; Peptostreptococcus species, 91%; non-spore-forming gram-positive rods, 71%. Temafloxacin inhibited 91% of B. fragilis strains and 87% of other B. fragilis group species at 4 micrograms/ml. All strains of other Bacteroides species, 78% of Fusobacterium species, 80% of Clostridium species, and 90% of Peptostreptococcus species were inhibited at 4 micrograms of temafloxacin per ml.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1317149      PMCID: PMC189287          DOI: 10.1128/AAC.36.1.239

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

Review 1.  Susceptibility testing of anaerobic bacteria: myth, magic, or method?

Authors:  H M Wexler
Journal:  Clin Microbiol Rev       Date:  1991-10       Impact factor: 26.132

2.  Comparative activity of ciprofloxacin against anaerobic bacteria.

Authors:  V L Sutter; Y Y Kwok; J Bulkacz
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

Review 3.  Antimicrobial resistance in Bacteroides.

Authors:  H M Wexler; S M Finegold
Journal:  J Antimicrob Chemother       Date:  1987-02       Impact factor: 5.790

4.  The antibiotic sensitivity of the Bacteroides fragilis group in the United Kingdom.

Authors:  A R Fox; I Phillips
Journal:  J Antimicrob Chemother       Date:  1987-10       Impact factor: 5.790

5.  Interactions of ciprofloxacin with clindamycin, metronidazole, cefoxitin, cefotaxime, and mezlocillin against gram-positive and gram-negative anaerobic bacteria.

Authors:  J L Whiting; N Cheng; A W Chow
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

6.  Comparative activity of the quinolones against anaerobic bacteria isolated at community hospitals.

Authors:  E J Goldstein; D M Citron
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

7.  The comparative in-vitro activity of eight newer quinolones and nalidixic acid.

Authors:  A King; I Phillips
Journal:  J Antimicrob Chemother       Date:  1986-11       Impact factor: 5.790

8.  Activity of pefloxacin and thirteen other antimicrobial agents in vitro against isolates from hospital and genitourinary infections.

Authors:  B M Jones; I Geary; M E Lee; B I Duerden
Journal:  J Antimicrob Chemother       Date:  1986-06       Impact factor: 5.790

9.  Comparative in vitro activity of lomefloxacin, a new difluoroquinolone.

Authors:  A M Clarke; S J Zemcov
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-02       Impact factor: 3.267

10.  Is ciprofloxacin active against clinically important anaerobes?

Authors:  B Watt; F V Brown
Journal:  J Antimicrob Chemother       Date:  1986-05       Impact factor: 5.790

View more
  12 in total

Review 1.  Current antimicrobial therapy of anaerobic infections.

Authors:  C V Sanders; K E Aldridge
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-11       Impact factor: 3.267

2.  In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria.

Authors:  H M Wexler; E Molitoris; D Molitoris; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

Review 3.  Quinolone activity against anaerobes.

Authors:  P C Appelbaum
Journal:  Drugs       Date:  1999       Impact factor: 9.546

Review 4.  Impact of the fluoroquinolones on gastrointestinal flora.

Authors:  V Korten; B E Murray
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 5.  Quinolone activity against anaerobes: microbiological aspects.

Authors:  P C Appelbaum
Journal:  Drugs       Date:  1995       Impact factor: 9.546

6.  E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens.

Authors:  J Guinea; D Gargallo-Viola; M Robert; E Tudela; M A Xicota; J Garcia; M Esteve; R Coll; M Pares; R Roser
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

7.  In vitro activity of DU-6859a against anaerobic bacteria.

Authors:  H M Wexler; E Molitoris; D Reeves; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

8.  In vitro activity of Bay Y3118 against anaerobic bacteria.

Authors:  H M Wexler; E Molitoris; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

9.  In vivo efficacies of quinolones and clindamycin for treatment of infections with Bacteroides fragilis and/or Escherichia coli in mice: correlation with in vitro susceptibilities.

Authors:  I Brook
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

10.  Comparative transcription analysis and toxin production of two fluoroquinolone-resistant mutants of Clostridium perfringens.

Authors:  Sunny Park; Miseon Park; Fatemeh Rafii
Journal:  BMC Microbiol       Date:  2013-03-01       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.